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Abstract 
The transglycosylase Saccharomyces cerevisiae Gas2 (ScGas2) belongs to a large 
family of enzymes that are key players in yeast cell wall remodeling. Despite its 
biological importance, no studies on the synthesis of substrate-based compounds as 
potential inhibitors have been reported. We have synthesized a series of docking-guided 
glycomimetics that were evaluated by fluorescence spectroscopy and saturation-transfer 
difference (STD) NMR experiments, revealing that a minimum of three glucose units 
linked via a β-(1,3) linkage are required for achieving molecular recognition at the 
binding donor site. The binding mode of our compounds is further supported by STD-
NMR experiments using the active site-mutants Y107Q and Y244Q. Our results are 
important for both understanding of ScGas2-substrate interactions and setting up the 
basis for future design of glycomimetics as new antifungal agents. 
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1. Introduction 
 
Enzymes that can transfer single or multiple activated carbohydrate units to a 
range of substrates are involved in important biological processes and therefore are 
potential pharmaceutical targets.
1
 In particular, transglycosylases that belong to GH72 
in the CAZy database
2
 are ubiquitous enzymes present in fungal organisms. These 
glycosylphosphatidylinositol (GPI)-anchored enzymes are crucial for remodeling of 
fungal cell wall,
3
 which is an essential structure in scaffolding the cytoplasmic 
membrane and maintaining structural integrity of those microorganisms. While some 
information about the enzymes responsible for the cell wall biosynthesis is available,
4
 
little is known of the involvement of these transglycosylases in the construction and 
remodeling of the fungal cell wall.
5
 
These transglycosylases are classified as glycosylhydrolases due to their typical 
folding, which consists of a TIM barrel domain formed by (βα)8.
6,7
 Although the overall 
structure resembles a glycosylhydrolase, its activity shows a balance among hydrolysis 
and transglycosylation depending on the length of the substrate. For example, 
Saccharomyces cerevisiae Gas2 (ScGas2. Figure 1) is inactive against laminaripentaose 
(G5) but is a pure hydrolase against laminarihexaose and heptaose and becomes a 
transglycosylase against larger-sized laminarioligosaccharides.
7
 In the case of 
Aspergillus fumigatus  Gel1, laminarinonaose was the minimal tested size to have 
transglycosylase activity.
8
 Several efforts have been made on elucidating the 
mechanism of action of transglycosylases
9
 and several antibiotics that inhibit the 
transglycosylation step in bacteria have been designed.
10
 
This family of fungal enzymes has key important biological roles in yeast and 
fungi and in some cases are even essential for pathogens such as Aspergillus 
fumigatus.
11
 Consequently, the targeting of these enzymes with specific inhibitors might 
represent potential therapies to treat selectively fungi-related pathologies like 
Aspergillosis and Candidiasis that constitute important current medical problems.
12 
Despite of their biological importance, the unique enzyme from this family 
whose tridimensional structure is described is ScGas2.  Several X-ray structures have 
been resolved,
7
 including the apo-structure (E176Q mutant, PDB entry 2W61) and 
structures in complex with laminaripentaose (PDB entry 2W62) and with laminaritriose 
and laminaritetraose (PDB entry 2W63). From these crystallographic data, the 
architecture of this family of enzymes was described and their catalytic mechanism was 
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proposed. The active site of ScGas2 shows two catalytic residues, the nucleophile E275 
and the acid-base E176, and four well conserved tyrosine residues (Y107, Y244, Y307 
and Y316). To explain the transglycosylation mechanism, the “base occlusion 
mechanism” was proposed, in which the leaving hydrolyzed sugar blocks the entrance 
of a key water molecule and thus avoids hydrolysis, favoring transglycosylation.
7
 
 
 
Figure 1. Surface representation of ScGas2 in complex with two G5 units at donor 
(positions -5 to -1) and acceptor (positions +1 to +5) sites 
 
Our aim is to design glycomimetics as potential inhibitors targeting essential 
transglycosylases of the fungal cell wall. In particular, it is well known that Gel4, a 
homologue of ScGas2, is essential in Asp. fumigatus, and consequently the design of 
glycomimetics for this enzyme might become future drugs to treat Aspergillosis. Due 
that we could only express and purify ScGas2, we decided to use ScGas2 as a template 
for AfGel4. The study of the identity between ScGas2 and different homologues were 
already reported
7
 and from this data it was very clear that overall all members of this 
family conserve all the important residues involved in catalysis and sugar recognition. 
Of note, ScGas2 might serve as a template to discover inhibitors for AfGel4 given the 
high identity among them at the active site level (the identity between the catalytic 
domains is ~50% and reaches 100% when all the key residues recognising the 
carbohydrates from -3 to +1 are considered). This makes ScGas2 very appealing for the 
design of new glycomimetics not only targeting ScGas2 but also AfGel4.  Recently, we 
developed a synthetic strategy for the preparation of O- and C-glycosides derived from 
β-(1,3)-D-glucans13 that demonstrated its utility for the synthesis of di- and trisaccharide 
analogues. 
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Herein, we have further explored the combination of different radicals 
covalently bound to variable laminooligosaccharides; in particular, we fixed our 
attention on compounds 1-3 (Figure 2). The interactions of these compounds with 
ScGas2 were analyzed by computational molecular docking studies, STD-NMR 
experiments and tryptophan fluorescence spectroscopy, and applied this information to 
unambiguously determine the minimal substrate length required for the design and 
synthesis of glycomimetics for the ScGas2 enzyme. 
 
 
 
Figure 2. O-glycosides derived from β-(1,3)-D-glucans 
 
2. Materials and Methods 
NMR Studies 
NMR spectra were recorded in a Bruker 500MHz spectrometer, equipped with a direct 
TBO probe. 
1
H spectra were recorded with water signal suppression using excitation 
sculpting with gradients (Pulse program zgesgp). Water saturation pulse was adjusted to 
2 ms with a Sinc1.1000 shape. Saturation Transfer Difference spectra were acquired 
with water suppression using excitation sculpting with gradients (Pulse program 
stddiffesgp.3). Protein saturation pulse was adjusted to 50 ms, with an Eburp2.1000 
shape during 2 s. Saturation frequency was optimized to -0.5 ppm when on resonance 
and 40 ppm when off resonance. Relaxation delay was adjusted to 1.5 s and acquisition 
time to 2.5s. For both on- and off-resonance, 1024 spectra were acquired. Sample 
temperature was fixed to 298 K. All measured samples were prepared on deuterated-
TRIS 25 mM in deuterium oxide at pH 8.0, dissolving ligand to 1mM and 
corresponding protein to 20 μM. STD spectra were recorded with separated solution 
components to check blank. Only protein signals between 1.25 and 0.50 ppm appear as 
background, and the TRIS signal at 3.60 ppm. 
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Docking Studies 
Compounds 1-3 were docked into the catalytic site of ScGas2 (PDB ID 2W62) using 
Glide software from Schrödinger. Protein was prepared with the Protein Preparation 
Wizard, water molecules and the acceptor oligosaccharide were removed. Grid was 
prepared with a box size of 45x45x45Å, centred on the donor oligosaccharide, using 
OPLS-2005 force field. Ligands were designed with Maestro, prepared with LigPrep 
and minimized using Gaussian 09,
14
 with a convergence threshold of 0.05 and 5000 
maximum iterations. Afterwards, MacroModel was used to generate 1000 different 
conformations for each ligand. Glide was run on XP mode (Extra Precision) using as 
input all calculated conformations. Schrödinger Suite 2013 was used for all 
computational calculations: Maestro 9.4 for viewing and protein preparation; LigPrep 
2.6 for ligand preparation; MacroModel 10.0 for ligand energy minimization; Glide 5.9 
for molecular docking. 
 
Cloning, expression and purification. 
The cloning was carried out as described before
7
 with the exception that the DNA 
sequence encoding to the amino acids residues 26-525 of the S. cerevisiae Gas2 which 
was obtained by PCR from the S. cerevisiae strain BY4741 kindly provided by Prof. 
Javier Arroyo (Universidad Complutense de Madrid, Spain). The double mutant 
N498D/N510D, referred to here as the wild type, and the mutants Y244Q and Y107Q 
were also generated as shown before.
7
 
The expression system used was Pichia Pastoris strain X33 (Invitrogen). Batch cultures 
were performed in 1 liter of BMGY medium (1% (w/v) yeast extract, 2% (w/v) peptone, 
100 mM potassium phosphate (pH 6.0), 1.34% (w/v) yeast nitrogen based and 1% (v/v) 
glycerol) overnight at 30 ºC, then centrifuged at 4000 g for 10 minutes. Cells were 
resuspended in BMMY medium (1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate pH 6.0, 1.34% (w/v) yeast nitrogen base and 1% (v/v) methanol) 
and incubated at 18ºC. Supernatant containing ScGas2 and mutants were collected after 
72 hours of methanol induction and concentrated to 20–50 ml using a Pellicon XL 
device (Millipore), and dialyzed against 25 mM Tris and 5 mM sodium phosphate pH 
7.5. Samples were loaded into 1 x 5 ml CHT Type I cartridge (Bio-Rad), previously 
equilibrated with 25 mM Tris and 5 mM sodium phosphate pH 7.5. The protein was 
eluted with a sodium phosphate gradient (5-500 mM). Gel filtration was carried out 
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using Superdex 75 XK26/60 column in buffer containing 25 mM Tris pH 7.5 and 150 
mM NaCl. The protein was dialysed in Tris-HCl 25 mM pH 7.5.  
 
Fluorescence spectroscopy assay 
Fluorescence spectroscopy assay was carried out to evaluate the dissociation constants 
of ScGas2 WT against compounds 1-3. These experiments were conducted in a Cary 
Eclipse spectrofluorometer (Varian) at 25 ºC. Protein concentration was 1 µM in every 
case and concentration of compounds 1-3  varied from 0.1 mM to 4 mM in buffer 25 
mM Tris pH 7.5. Fluorescence emission spectra were registered in the 300-450 nm 
range with an excitation wavelength of 280 nm. 
Data analysis was performed in Prism (GraphPad Software) according to the fitting 
equation below: 
 
 
Inhibition assays 
Activity was measured monitoring laminarihexaose (G6) hydrolysis obtaining as major 
products laminaritetraose , laminaritriose and laminaribiose. Reactions took place at 
30ºC on a final volume of 100 µL of ammonium formate buffered solution (10 mM) at 
pH 5.5, containing fixed concentrations of ScGas2 (5 µM) and G6 (0.5 mM, 
Megazyme, Ireland) and variable concentrations of compound 3 (100 µM, 200 µM, 500 
µM, 1 mM, 2 mM and 5 mM). Reaction was monitored every 30 minutes, over 3 hours, 
with 2 repetitions. Hydrolysis ratio was determined by comparison of G6 concentration 
(mean of 2 measurements). IC50 was calculated by extrapolating the inhibitor 
concentration at which G6 hydrolysis is half of obtained in absence of compound 3. 
Oligosaccharides were determined by UPLC chromatography on a 2.1 mm i.d. x 50 mm 
ACQUITY 1.7 µM BEH Amide (Waters Corp, USA) using an ACQUITY UPLC 
system (Waters Corp., USA). The column was maintained at 35ºC. Mobile phase, at a 
flow rate of 0.800 mL/min, consisted of 68% acetonitrile and 32% water, both solvents 
doped with 0.2% triethylamine. 1 µL of sample was injected without any pretreatment. 
Carbohydrates were detected with an Evaporative Light Scattering Detector (ELSD, 
Waters Corp. USA) with optimized conditions as follows: temperature of drift tube 
100ºC, nebulizer temperature 45ºC, gain 1000, and nitrogen pressure 30 psi. G6 
retention time, on these conditions, is 58-62 seconds. 
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3. Results 
Compounds 1-3 were prepared by glycosylation of the corresponding glycosyl 
bromide, derived from peracetylated laminarioligosaccharide following the procedure 
we described previously
13 
(Scheme 1).  Spectroscopic data for compounds 1-3, as well 
as for intermediates are available in the Supporting Information.  
 
Scheme 1. Synthesis of compounds 1-3. (i) 30% HBr, AcOH, rt, 15 min (76%). (ii) 
Ph(CH2)5OH, AgCO3, CH2Cl2, rt, 20 h (63%). (iii) NaOMe, MeOH, rt, 4 h (quant.). 
 
Docking studies were initially performed with G5 on the entire enzyme ScGas2 
(PDB code 2W62) using the Schrödinger Software.
15
 Analogous studies were done with 
glycomimetics 1-3 and the best affinity was observed for compound 3.  Differences of 
ca. 9 and 4 kcal/mol were found between the lowest energy representative cluster for 
compound 3 and for compounds 1 and 2, respectively (Figure 3). Calculations with 1-3 
revealed notable differences in binding energy for each derivative with ScGas2. 
Furthermore, poses obtained for each compound showed a different dispersion on their 
geometry. In particular, compound 3 showed lower pose dispersion around the 
minimum energy pose. 
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Figure 3. Graphical representation of Glide Docking Energy (Kcal/mol) vs. 
RMSD calculated from the lowest energy pose for each product, being 1 (blue), 2 
(green) and 3 (red).  
 
 
STD-NMR experiments
16,17 
 were measured on the corresponding ligand and 
ScGas2 mixtures. STD-NMR spectra showed depreciable signal for compound 1 
(Figure 4, traces A and B), but a slight STD signal for compound 2 (Figure 4, traces C 
and D). In this latter case, a STD signal corresponding to aromatic protons, with an 
enhancement of 1% could be observed; methylene groups showed an enhancement 
below 1%. On the other hand, no STD signal was observed for glucose moieties. STD 
spectrum for compound 3 showed more intense signals for the whole molecule than the 
other two compounds (Figure 4, traces E and F). Under the same conditions both the 
aromatic ring and the pentyl spacer showed an enhancement of 3%. Laminaritriose 
signal showed a STD enhancement of 1% (except those lost due to solvent suppression). 
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Figure 4. 
1
H spectra and STD-NMR spectra measured for compounds 1-3. STD spectra 
are scaled up 64 times. Traces A and B correspond to compound 1; traces C and D 
correspond to compound 2; traces E and F correspond to compound 3. 
 
A comparison of the STD-NMR experiments carried out with the wild-type 
protein (Figure 5, trace D), and mutants Y244Q (Figure 5, trace B) and Y107Q (Figure 
5, trace C), shows an complete disappearance of STD signals for the Y244Q mutant, 
and an enhancement below 1% for aromatic and methylene protons when Y107Q 
mutant is present. 
 
1H-spectrum
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B
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D
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F
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Figure 5. STD-NMR spectra for Y244Q mutant (trace B), Y107Q mutant (trace C) and 
the wild type enzyme (trace D) with 3. 
1
H NMR spectrum of compound 3 is given in 
trace A. 
 
Tryptophan fluorescence studies (Figure 6) provided for compound 3 Kd of 800 ± 100 
µM. Unlike compound 3, compounds 1 and 2 did not show dose-response changes 
impeding to obtain Kd values. 
 
Figure 6 Quenching of intrinsic ScGas2 tryptophan fluorescence measured at increasing 
concentrations of the compound 3. All data points represent the means ± S.D. for three 
measurements. The Kd for compound 3 was determined by fitting fluorescence intensity 
data against compound 3 concentration. 
 
Inhibition data was obtained by measuring the hydrolytic activity of the enzyme. 
Laminarihexose (G6) has been used as the substrate for hydrolysis, mainly rendering 
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laminaribiose, laminaritriose and laminaritetraose without any measurable 
transglycosylation activity.
7
 Determination of the hydrolytic activity of ScGas2 in the 
presence of compound 3 rendered an IC50 value of 1.55 mM. No effects on 
laminarihexaose hydrolysis were observed when 1 and 2 were added to the reaction. An 
additional reaction was monitored containing 3 (2 mM) and ScGas2, in absence of 
substrate (G6). No evolution was observed over 24 hours at 30ºC. 
 
 
Figure 7 Evolution of G6 hydrolysis in the presence 3 in different concentrations.  
 
4. Discussion 
 
Docking results clearly match the previously described binding mode of G5
7
 
(RMSD of 0.35 Å and 0.12 Å for sugars adopting the lowest representative energy 
cluster located from -5 to -1, and +5 to +1, respectively) and reveal a higher affinity of 
G5 for the donor site than for the acceptor site of the protein (Figure 8, top panel). 
Indeed, it is observed a strong correlation between the G5 binding mode with the lower 
energy calculated poses. These docking studies showed that the conformation of 
residues in positions -2 and -3 did not change to a large extent, remaining fixed by 
several H-bond interactions (Figure 8, bottom panel). 
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Figure 8. Close-up view of the ScGas2 crystal structure in complex with G5 (top 
panel), and the minima energy poses calculated for the complex within a 1 kcal/mol 
energy difference (bottom panel) 
 
On the other hand, residues on -4 and -5 positions, located far from the reaction 
site, show higher flexibility in all studied conformations. Residue on position -1 is 
involved in CH-π interactions with the phenyl ring of amino acid residue Y107 and a 
key H-bond with hydroxyl group on resdidue Y307. In addition, the reaction site is also 
characterized by the presence of a hydrophobic pocket formed by the side chains of 
residues Y244, Y307 and Y316. Thus, our in silico study allowed us to conclude that 
the enzyme shows higher affinity for sugars at position -3 and -2, suggesting that 
potential glycomimetics should contain at least 2 units of glucose, specifically β-(1,3) 
bonded.. The presence of that hydrophobic pocket prompted us to consider 
glycomimetics containing aromatic radicals, such as compounds 1-3, as good candidates 
for binding the active site.  
The most representative poses obtained from docking studies for compounds 1-3 
are illustrated in Figure 9 (top panel). In all cases, the carbohydrate units remains at the 
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donor site. Compound 3 is the only one occupying positions -1 to -3, as found for the 
natural substrate. In fact, calculated RMSD for the carbohydrate moiety between 
laminaripentaose from the PDB entry 2W62 and compound 3 is 0.174 Ǻ, being the 
maximum deviation of 0.291 Ǻ. Furthermore, the fact of 3 occupying the -1 position 
with the functionalized ring allows the phenylpentyl moiety to overpass catalytic 
residues E176 and E275, and place the phenyl group in the hydrophobic pocket, formed 
by Y244, Y307 and Y316. An edge-to-face π-π stacking of the phenyl group with Y244 
is clearly evidenced (Figure 9, bottom panel).  
 
 
Figure 9. Most representative poses for compounds 1 (blue), 2 (green) and 3 (red) 
bounded to ScGas2 (top panel). Close-up view of the compound 3 docked into the 
active site of ScGas2 (bottom panel). 
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STD-NMR experiments were designed to confirm our docking results. Comparing 
derivatives 1-3 spectra (Figure 4), the highest signal intensity for all protons from 3 
clearly indicates that its affinity is higher than the other two glycomimetics. Besides, 
regarding the relative intensities between the aglycone protons and the carbohydrate 
signals, it can be inferred that the phenylpentylgroup is the anchoring moiety that 
enhances the interaction with the protein. STD-NMR experiments with mutants confirm 
this hypothesis. The complete loss of STD signal observed for Y244Q mutant (Figure 5, 
trace B) demonstrates the interaction of phenyl group with the tyrosine-rich pocket, in 
particular the proposed π-π stacking with precisely Y244. In the case of Y107Q mutant 
(Figure 5, trace C) only phenylpentyl group interaction remains, meaning the loss of the 
carbohydrate moiety interaction. These experimental studies support the binding mode 
of compound 3 that is inferred from docking and previous STD-NMR studies.  
Tryptophan fluorescence studies confirm that compounds 1 and 2 have a very low 
affinity and that compound 3 is the best compound of our series, showing a Kd of 800 ± 
100 µM. This value is significant since affinity of ScGas2 with its own substrates is so 
low that it cannot be measured, so the introduction of the aromatic moiety, conveniently 
linked to laminaritriose has been able to increase the affinity, probably, an order of 
magnitude. 
The inhibition assay let us confirm that glycomimetic 3 is able to bind the active site 
of ScGas2 better than a substrate as laminarihexaose. Unfortunately, the IC50 value is 
too high to consider 3 as a good inhibitor. It is also remarkable that no hydrolysis of 
compound 3 occurs in presence of ScGas2. 
 
5. Conclusions 
These studies open a door for a rational design of compounds that could inhibit ScGas2 
and close homologues such as Aspergillus fumigatus Gel4, that in turn is a drug target 
for Aspergillosis. We clearly demonstrate that a minimum of three monosaccharide 
units are required for ensuring a correct recognition at the donor binding site of the 
enzyme, and  that the correct orientation of the hydrophobic radical towards the 
hydrophobic pocket increases the affinity of the ligand. This is supported by STD-NMR 
experiments that suggested that the hydrophobic radical acts as an “anchoring moiety” 
for the glycomimetics. Also, from the docking studies it appears that the representative 
poses present a CH-π interaction between the phenyl group and residue Y244. STD-
NMR experiments also showed that the affinities observed with wild-type ScGas2 are 
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completely loss with the corresponding mutants Y107Q and Y244Q, thus confirming 
the specific interactions between these residues and the sugar at position -1 and the 
hydrophobic radical. Fluorescence studies and inhibition experiments also confirmed 
the above results. Further design of other trisaccharide analogues bearing other groups 
at the anomeric center of residue -1 are currently being pursued and they will be 
reported in due course. 
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